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Abstract 
Background 
Proton pump inhibitors (PPIs) are widely used drugs in the United States. Atrial 
fibrillation (AF) affects 2.7 million people in this country and often leads to other serious 
medical conditions. There is a growing body of evidence suggesting that PPIs may be 
proarrhythmic. This study seeks to better appreciate the relationship between these 
popular drugs and the most common arrhythmia. 
Methods 
This is a nested case-control study using a large, nationally representative insurance 
database. Members with an incident AF diagnosis between 2007 and 2009 were 
identified. Each case was matched with one control member, using incidence density 
sampling, and both were assigned an index date of the case’s date of AF diagnosis. PPI 
exposure was assessed through pharmacy claim records for both cases and controls prior 
to their assigned index date. Multivariable analysis was accomplished through 
conditional logistic regression as a means of comparing PPI exposure among cases and 
controls. 
Results 
The study included 40,484 eligible members (20,265 cases and 20,219 controls). 
Bivariate analyses revealed that cases were more likely to have each of the potentially 
confounding comorbidities of interest than controls. An unadjusted multivariable analysis 
suggested that cases were more likely to have redeemed a PPI prescription OR= 3.53 
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[3.12 – 3.99]. Following adjustment, the association diminished but remained significant 
OR= 1.98 [1.63 – 2.41]. A sensitivity analysis among cases and controls with redeemed 
prescriptions for PPIs and H2RAs failed to suggest that cases were significantly more 
likely to have been exposed to PPIs OR= 1.68 [0.88 – 3.19]. 
Conclusions 
Exposure to PPI therapy was more likely among those with an incident AF diagnosis. 
This study is in agreement with similar findings that PPIs may cause arrhythmias. 
However, the insignificance of the sensitivity analysis weaken the study’s ability to 
declare with more certainty that the observed association between PPIs and AF are 
independent of GERD, which has also been hypothesized as a causative condition of AF. 
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Literature Review 
The following review of the literature is a summary of key concepts foundational to the 
understanding of proton pump inhibitors, atrial fibrillation, and their potential 
association. The works cited were located primarily using PubMed.gov and Web of 
Science™ through the University of Kentucky Medical Center Library website. PubMed 
searches used include: “atrial fibrillation and proton pump inhibitors” (atrial fibrillation 
plus each individual proton pump inhibitor e.g. “atrial fibrillation and omeprazole” were 
also conducted searches), “atrial fibrillation and hypomagnesaemia”, and 
“hypomagnesaemia and proton pump inhibitors” as well as hypomagnesaemia plus 
individual proton pump inhibitors. Additional key references were recommended by 
instructors providing guidance. Works cited include predominantly observational studies, 
case reports, and clinical guidelines from the disciplines of gastroenterology, cardiology, 
and pharmacology.  
An Introduction to PPIs 
Proton pump inhibitors (PPIs) are widely prescribed drugs that suppress the secretion of 
gastric acid. Currently available PPIs in the United States include: omeprazole, 
esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole. They are all 
available by prescription, while omeprazole, esomeprazole, and lansoprazole are also 
available as non-prescription medications.  PPIs are the most potent acid-suppressing 
drugs used to treat esophagitis and gastroesophageal reflux disease (GERD)12 and they 
play an important role in managing both acute and chronic peptic ulcer disease.1 3 In 
2011, omeprazole was the sixth most dispensed prescription in the United States4 and its 
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actual use may be underestimated due to its availability without a prescription since 2003. 
Indeed, the class as a whole remains popular and accessible as generic versions of 
omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole are now 
available.   
PPIs are often the drug of choice for the treatment of reflux symptoms. They are superior 
to other shorter-acting, acid-lowering therapies due to their ability to maintain intragastric 
pH <4 between 15 and 21 hours.5 Their popularity in the United States is largely due to a 
high prevalence of GERD. It has been estimated that 23% to 27% of United States adults 
experience reflux symptoms at least weekly.6 Estimates for the prevalence of regularly 
experienced heartburn, the most characteristic symptom of GERD, in western countries 
may be as high as 40%.7 Initial GERD treatment recommendations focus on lifestyle 
modifications, including weight loss and tobacco cessation, but pharmacological therapy 
is frequently instituted.8 Also adding to the popularity of PPIs is their use in hospitals. 
Admitted patients are frequently prescribed PPIs as a method of stress ulcer prophylaxis 
and often do not have the order discontinued at discharge.8 9 
Hypomagnesaemia 
While therapeutically useful, PPIs are not without the risk of adverse reactions. All PPI 
therapy poses the risk of common pharmaceutical adverse reactions such as headaches, 
dizziness, and gastrointestinal disturbances.10 A more unique effect of long-term PPI 
therapy that has recently garnered more attention is hypomagnesaemia.  
In response to increased reports of low serum magnesium levels during PPI therapy, the 
FDA notified healthcare professionals and the public in 2011 of the association between 
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hypomagnesaemia and PPI therapy of at least three months. The FDA recommended that 
clinicians consider obtaining serum magnesium levels prior to initiation of PPI therapy 
and periodically thereafter.11 Case reports121314 and a systematic review15 demonstrate 
that PPI-induced hypomagnesaemia, while relatively rare: is a class effect, resulted in 
severe symptoms due to magnesium deficiency, and was frequently resolved only by the 
removal of a PPI. 
Atrial Fibrillation 
Magnesium is required for more than 200 biochemical reactions in the human body. In 
addition to maintaining normal nerve and muscle function, supporting immune systems, 
and helping bones remain strong, it allows for a normal heart rhythm.16 
Hypomagnesaemia is known to be associated with cardiac arrhythmias17 and was shown 
to be associated, specifically, with atrial fibrillation (AF) in Framingham offspring 
without cardiovascular disease.18  
As the most common form of arrhythmias,19 AF affects an estimated 2.7 million in the 
United States. It is a quivering or irregular heartbeat that may produce blood clots, 
strokes, and other cardiovascular complications.20 There are more than 467,000 
hospitalizations with AF as the primary diagnosis in the United States annually and it is 
estimated that AF contributes to more than 99,000 annual deaths.21 The most concerning 
aspect of AF is that it often leads to other medical conditions. AF is associated with a 
five-fold increased stroke risk22 and AF-related strokes are likely to be more severe than 
non-AF-related strokes.23 Additionally, AF is associated with a three-fold increased risk 
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of heart failure,242526 a two-fold increased risk of dementia,27 and an overall two-fold 
increased risk of mortality.22 
GERD and AF  
Given the popularity of PPIs, the pervasiveness of AF, and the intermediate 
hypomagnesaemia association- we seek to further examine the association between PPIs 
and AF. The theory that PPI therapy may increase the risk of AF has not been sufficiently 
investigated. This theory is further complicated by the most common indication of PPI 
therapy, GERD. There are studies suggesting that GERD, the condition itself, increases 
the risk of developing AF.  
Multicenter questionnaire surveys have found significant correlations between AF and 
GERD among respondents.2829 Kunz, et al. published findings of a retrospective, 
epidemiologic study that investigated the association between GERD and AF diagnoses 
among 163,627 adult patients. They found that the presence of GERD significantly 
increased the relative risk (RR) of a diagnosis of AF after adjusting for cardiovascular 
disease risk factors (RR: 1.19, 95% CI: 1.13-1.25) and diagnoses known to be strongly 
associated with AF (RR: 1.08, 95% CI: 1.02-1.13).30 It is worth noting that at least one 
large population-based study of patients surveyed for GERD did not find an association 
with the presence of GERD symptoms and AF. Long-term risk for AF was determined by 
a review of clinical evaluations and electrocardiographic database and found that 741 of 
the respondents developed AF. Following adjusting for confounders, the presence of 
GERD was not associated with risk of developing AF (HR: 0.81, 95% CI: 0.68-0.96, 
p=0.014).31 
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Huang, et al. conducted a prospective, epidemiologic study using Taiwanese national 
health insurance data that followed 29,688 newly diagnosed GERD patients and 29,597 
controls. They observed that 184 patients (0.62%) with GERD experienced an occurrence 
of AF, while 167 patients (0.56%) non-GERD patients also received a diagnosis of AF. 
The investigators found that, following a Cox proportional-hazard model analysis, GERD 
was independently associated with an increased risk of developing AF (hazard ratio 
(HR): 1.31, 95% CI: 1.06-1.61, p=0.013).32 
While the actual mechanism by which GERD may lead to AF is still undetermined, 
Huang, et al. detail several causal theories. GERD may induce vagal nerve 
stimulation,3334 and animal and human studies have observed that vagal nerve 
overstimulation may be related to the induction of AF.3536 There has also been an 
observed relationship between AF and cardiac inflammation.37 The anatomical proximity 
between the atria and esophagus38 and the local inflammatory process observed in 
GERD39 provide another theoretical mechanism by which GERD induces AF. Another 
theory proffers that GERD may induce an autoimmune response that contributes to the 
development of AF.40 Lastly, acidic stimulation of the lower esophagus has been shown 
to significantly reduce coronary blood flow within coronary artery disease patients41; 
chronic atrial ischemia has been suspected to predispose individuals to AF.42  
The Taiwanese investigators also performed a sensitivity analysis for PPI administration 
for GERD. Among GERD patients, 12,862 received PPIs and 16,826 did not. GERD 
patients who received PPI therapy were found to have an increased risk of AF (HR: 1.46, 
95% CI: 1.15-1.86, p=0.002) but GERD patients who were not prescribed a PPI were not 
found to have an increased risk of developing AF (HR: 1.14, 95% CI: 0.86-1.51, 
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p=0.378). The investigators suggested that GERD that produces significant enough 
symptoms to merit PPI therapy has a higher risk of AF. Huang, et al. admittedly point out 
that this interpretation could be flawed due to the availability of reports demonstrating 
that PPIs may be proarrhythmic.32 
 
FIGURE 1 
 
 
 
 
 
 
 
PPI may be proarrhythmic 
Marcus, et al. performed a case-control study reviewing 80 patients with focal 
tachycardias: 40 patients with focal atrial tachycardia (AT) and 40 patients with right 
ventricular outflow tract (RVOT) automaticity, designated as the cases. They used 80 
patients with arrhythmias not attributable to increased automaticity as the control group. 
After adjustment for potential confounders, PPI use was found to be significantly 
associated with focal arrhythmias (OR: 5.2, 95% CI: 1.4-19.2, p=0.025).43  
PPI	   A	  Fib	  
Mg	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The investigators discussed potential PPI-induced proarrhythmic  mechanisms to explain 
their findings including evidence of H+/K+-ATPase activity in cardiac muscle. Proton 
pump inhibitors function by irreversibly blocking this enzyme system (also referred to as 
the proton pump) and it has also been reported to be present in the myocardium of 
animals4445 and humans.46 However, the expression of the pump appears to be very low in 
myocardium compared with gastric tissue and no relevant changes in pH homeostasis 
were detected in the study from Schillinger, et al. that first reported the presence of the 
pump in human ventricular myocardium. The effects of PPIs on cardiac contractility, 
according to Schillinger, et al., involve intracellular mechanisms that are distinct from 
their effects in gastric tissue, and possibly related to increased intracellular calcium.46 
There has been a reported association between increased intracellular calcium and 
catecholaminergic polymorphic ventricular tachycardias.47 Marcus, et al. point out, 
because intracellular calcium regulation is vital to normal myocardial automaticity, 
common forms of triggered and automatic arrhythmias like AT and RVOT could arise 
from abnormal intracellular concentrations.4849 
While arrhythmias induced by calcium abnormalities are certainly not baseless, there is 
still much undetermined in the development of abnormal cardiac rhythms. Often, the 
interpretation and comparability of studies is difficult due to differences in many known 
arrhythmias and due to associated electrolyte abnormalities.  For example, magnesium 
deficiencies are often accompanied by hypokalemia, hypophosphatemia, hyponatremia, 
and hypocalcemia.50 Concomitant deficiencies of both magnesium and calcium have been 
well described and magnesium concentrations (intracellular and extracellular) also have 
an effect on the currents and transport capabilities of potassium and sodium51, other 
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important electrophysiological  determinants. As an established cofactor in the Na+/K+-
ATPase enzyme system that manages sodium and potassium flux across cell membranes, 
magnesium plays a role in maintaining the potential required for the depolarization of 
cardiac muscle. 
The proarrhythmic effects of PPIs remain controversial. In a two-year observational study 
of patients with paroxysmal, vagal AF who reported retrosternal and epigastric pain, 
Stöllberger, et al. followed 18 patients with PPI therapy. The investigators observed that 
patients’ pain and inflammation were reduced and also that AF attacks either stopped 
completely or were decreased in frequency. They suggested PPIs in these patients may 
have facilitated cardioversion and a maintenance of normal sinus rhythm.52 Similarly, 
another observational study from Weigl, et al. observed that not only GERD symptoms, 
but also paroxysmal AF symptoms were eliminated or decreased in 14 of 18 patients 
following PPI therapy. Five of the patients were even able to discontinue antiarrhythmic 
drugs.53 
Conclusions 
 There is an insufficient amount of evidence to definitively elucidate the relationship 
between PPIs and AF.  Despite the ubiquitous use of PPIs, the FDA’s warning that PPIs 
may cause hypomagnesaemia, and the Framingham observation linking 
hypomagnesaemia and AF, there remains a dearth of relevant studies concerning the 
popular drug class and the most common arrhythmia, which is a major contributor to 
morbidity and mortality in the United States. Among the many post-market reports 
concerning PPI safety, several case reports have documented a newly diagnosed 
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arrhythmia with PPIs being the only plausible causative agent. These patients shared 
many laboratory abnormalities, including hypomagnesaemia, and saw a restoration of 
normal sinus rhythm following the discontinuation of the PPI.545556  
This case-control study seeks to add to the body of evidence exploring the association 
between PPIs and AF. Although adverted by multiple case reports, we seek to appreciate 
this relationship on a population level. We anticipate that the findings of this large case-
control study will provide a fair estimate of the relationship between PPIs and AF, adding 
to the small, but compelling study from Marcus, et al. on focal arrhythmias. Previous 
observational studies have been large, but focused upon the association between GERD 
and AF. While most of these studies have found that GERD is associated with an 
increased risk of developing AF, it is possible that these studies are capturing the effect of 
an established biochemical adverse event of the popular drugs used to treat GERD 
symptoms. 
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Methods 
Introduction 
The authors adapted methods similar to the nested case-control study conducted by 
Schmidt, et al.57, which also investigated the association between drug exposure and 
atrial fibrillation.   
Study Design 
The authors conducted a nested case-control study using a large, nationally representative 
insurance database. The database contains medical claims from inpatient and outpatient 
encounters as well as pharmacy benefit utilization that include diagnoses and redeemed 
prescriptions. Claims were available for the years 2007 through 2009 and included 
approximately 22 million members for consideration. 
Cases and Controls 
Our outcome of interest was AF and patients with a first-time diagnosis of AF were 
identified and classified as cases.  To be eligible for inclusion, members were required to 
have shown continuous enrollment in their health care plan from January 1, 2007 through 
December 31, 2009. Any members with documented AF within the first three months of 
continuous enrollment were excluded. The date of the AF diagnosis was considered the 
index date for each case. One control was selected for each identified case using 
incidence density sampling.58 The controls were matched with each case and assigned the 
same index dates as their corresponding cases. 
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PPI use 
In order to assess the exposure of interest (PPIs), prescription claim records were 
explored for both cases and controls. Medication exposure was identified through an 
NDC AHFS crosswalk. Cases and controls that had at least one prescription redeemed for 
a PPI up to 90 days prior to their index date were considered “exposed” to PPI therapy. 
This exposure requirement was used to capture both 30-day supply and 90-day supply 
prescriptions that are commonly redeemed.  
Patient Characteristics 
In order to account for potential confounding variables, demographic information 
including age, gender, and race were collected for cases and controls and categorized as 
presented in Table 1. Diagnoses and redeemed prescriptions known to be associated with 
AF or reduced magnesium levels were also obtained for cases and controls and presented 
in Table 1. The following ICD-9 were used to identify diagnoses of interest: congestive 
heart failure (398.91 and 428.0), myocardial infarction (410.xx, 412, 429.71, and 429.79), 
diabetes mellitus (249.xx and 250.xx), hypertension (401.0, 401.1, 401.9, 405.01, 405.09, 
405.11, 405.19, 405.91, 405.99, 416.0, 459.30, 459.31, 459.32, 459.33, 459.39), valvular 
heart disease (093.20, 093.21, 093.22, 093.24, 394.9, 396.0, 396.2, 396.3, 396.8, 396.9, 
397.0, 397.1, 397.9, 424.0, 424.1, 424.2, 424.3, 424.90, 424.99, 999.02, 999.71), 
hyperthyroidism (242.xx), alcoholism (291.xx, 303.xx, 357.5, 425.5, 535.30, 535.31, 
571.xx), chronic kidney disease (403.xx, 404.xx, 585.xx), and overweight/obesity 
(278.00, 278.01, 278.02).  Potential confounders were identified a priori through 
literature review and clinical expertise of investigators. 
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Statistical Analysis 
Contingency tables were created to describe the relationship between the primary 
exposure of interest in cases and controls as well as potential confounders. From these, 
the frequency of cases and controls in categories of exposure and potential confounders 
of interest were calculated.  First, univariate analyses were calculated to explore the 
overall population characteristics using means and standard deviations for continuous 
variables and percentages. Bivariate analyses were used to examine unadjusted 
differences between cases and controls using Pearson’s chi-square test for categorical 
variables and t-tests for continuous variables. To examine the relationship between PPI 
exposure and AF in the presence of confounders, a multivariable analysis was conducted 
using conditional logistic regression to generate odds ratios and associated 95% 
confidence intervals. Conditional logistic regression is used to account for the incidence 
density sampling. All demographic and comorbidity categories displayed in Table 1 were 
considered for inclusion in the final model as all were shown to be associated 
significantly with both the outcome and exposure of interest. A final model was derived 
by examining the percent change in the estimated odds ratio natural log; variables were 
considered significant confounders and remained in the model if their absence generated 
a change in the natural log of the odds ratio estimate greater than ten percent. 
All data analysis was performed in STATA 13, made available by the University of 
Kentucky. 
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Results 
Table 1 presents descriptive data for the 40,484 members included in the study. The 
average age was 52 years (standard deviation: 22.61). More males (55%) were included 
than females. The largest racial group was white (79%). The most commonly 
documented co-morbidity of interest for all included members was hypertension (18.2%). 
Table 2 displays the frequency of the demographic information and variables of interest 
among the 20,265 cases and 20,219 controls. Those with AF were more likely to be 
older, male, and white than controls without AF. The large sample size generated 
statistical significance between the two groups for all collected demographic information, 
comorbidities, and drug exposures of interest. All comorbidities of interest occurred more 
frequently in members with AF than in those without. Of note, the following 
comorbidities were observed to have occurred in cases in at least a 10-fold increase to the 
proportion of controls: congestive heart failure (8.1% vs. 0.09%), hypertension (33% vs. 
3.2%), valvular disease (8.7 vs. 0.2%) and chronic kidney disease (2.6% vs. 0.2%). 
Table 3 displays results from an unadjusted and adjusted conditional logistic regression. 
An unadjusted conditional logistic regression to explore PPI exposure among cases and 
controls yielded an odds ratio (OR) of 3.53 (95% CI: 3.12 – 3.99, p<0.001) i.e. the odds 
of exposure to PPIs were 3.53 times more likely among those with incident AF than those 
without AF. Following adjustment for confounding factors, a final model demonstrated a 
reduced OR of 1.98 (95% CI: 1.63 – 2.41, p<0.001). 
A sensitivity analysis was performed among members exposed to PPIs and H2 receptor 
antagonists (H2RAs). H2RAs are another class of drugs used to treat GERD. Given the 
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body of evidence suggesting that GERD increases the risk of developing AF, the authors 
attempted to approximate a GERD variable (users of PPIs and H2RAs) and ascertain if 
there was a difference in PPI exposure among the cases and controls who were requiring 
acid suppression therapy. An unadjusted conditional logistic regression revealed a non-
significant OR of 1.68 (95%CI: 0.88 – 3.19, p=0.12). 
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Discussion 
This study found that members who had been diagnosed with AF were more likely to 
have redeemed a prescription for a PPI prior to their diagnosis than non-AF members 
prior to their assigned index date.  In agreement with Marcus, et al., this significant 
association on a population level suggests that PPIs may indeed be proarrhythmic. This 
study is also in agreement with Huang, et al. who found that PPI users were more likely 
than non-PPI users to develop AF among GERD patients. However the authors’ own 
sensitivity analysis among members receiving PPIs and H2RAs was not found to be 
significant. The small number of included members receiving H2RAs weakens the 
study’s ability to propose that PPIs, instead of GERD, are causative of AF. 
Strengths of this study include a large sample size. The large nationally represented 
database provided approximately 22 million members for consideration, of which 40,484 
were eligible for inclusion. This large sample size provides for a more reliable reflection 
of the relationship between these popular drugs and a common condition among the 
population. 
Another strength of this study is the use of incidence density sampling. Controls were 
selected from the members who were at risk at the time of an incident AF diagnosis. The 
use of incidence density sampling allows for the generation of an odds ratio that more 
closely approximates a risk ratio.  
A sensitivity analysis was attempted following the primary analysis of interest. The use 
of an appropriate comparison group, such as users of H2RAs, was another strength of this 
study that tried to better understand the true relationship of PPIs and AF. So long as 
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GERD and PPI exposure remains clinically intertwined, future studies will require similar 
sensitivity analyses to separate the effects of the condition from adverse events of the 
drug. 
One major limitation of this study was the absence of a minimal age requirement. The 
total sample of members was younger than anticipated. The youngest age group (0-49) 
included 40% of all cases and controls, while the mean age was 52 years. Of those 
belonging to the age group 0-49, 11.7% were cases and 88.3% served as controls. While 
age groups were accounted for in the final multivariable analysis, it cannot be ignored 
that many in the control group were children, as there was not a minimal age 
requirement.  This channeling bias may have affected the findings of this study and 
should be avoided in future related studies. The absence of AF in these younger members 
rendered them eligible to serve as controls for the purpose of this study. However, for 
many, their youthful protection from the development of AF also afforded protection 
from many of the gastrointestinal conditions for which PPI therapy is indicated. This may 
have led to an overestimation of the association between AF and PPIs. 
Another limitation stemming from patient characteristics is the under reporting of 
overweight and obese members. This study relied on ICD-9 coding to a health care plan, 
where height, weight, nor body mass index (BMI) were available for analysis. While in-
clinic counseling may have occurred for weight loss, its treatment is not covered by 
insurance companies.59 With little incentive to code a patient as overweight, it is likely 
that the proportion of overweight and obese members is severely underestimated. At the 
very least, the patient characteristics of this study sample fail to reach national CDC 
estimates that 69% of adults are at least overweight while obesity rates for children aged 
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2-5, 6-11, and 12-19 are 12.1%, 18.0%, and 18.4% respectively in the United States.60 
Obesity is a well-established risk factor for both AF61 and GERD symptoms62 and it 
could prove to be a greater confounding factor in related future studies. 
This study did not account for any drug therapy occurring beyond prescription coverage. 
The large, nationally represented insurance database facilitated a large study, but was 
incapable of reporting any drugs that were purchased without a prescription or were 
dispensed without billing the insurance plan. This limitation certainly applies to the use 
of NSAIDs and it would be ideal to have a more complete picture of NSAID usage 
among cases and controls. More critically, this limitation applies to omeprazole, the most 
popular PPI, which has been available without a prescription since 2003.  
We are unable to quantify with any certainty, the extent to which omeprazole was utilized 
beyond what pharmacy claims reveal. It is unknown if those purchasing omeprazole 
without a prescription are different than those who are having prescriptions filled, and 
billed, for the drug. It can be assumed that those who are more regular users of 
omeprazole would have prescription claims available for assessment as their co-pay 
would be more affordable than purchasing the drug without insurance. However, nothing 
is certain. The fact that omeprazole was available without a prescription for the duration 
of this study period means that omeprazole therapy was likely more common than the 
claims database suggests. This, likely, non-differential, misclassification may have lead 
to an underestimation of the association between AF and PPIs. 
The lack of prescription claims for H2RAs also limited the authors’ conclusions. The 
entire class of H2RAs (e.g. ranitidine, famotidine, etc) is relatively cheap and available 
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without a prescription. It is likely that their actual use has been under reported in the 
claims database. It is unknown how often they are truly prescribed, or at least, 
recommended by health care providers. H2RAs are used to address the symptoms of 
GERD, like PPIs. They are more rapid acting than PPIs, but ultimately do not possess the 
long-term acid-suppressing therapy provided by PPIs.  
The authors undertook a sensitivity analysis among PPI and H2RA users to better 
appreciate the relationship between AF and PPIs. The argument can be made that PPI 
prescription claims may just be a proxy for a GERD diagnosis. The large population-
based study of Huang et al. suggested that the presence of GERD increased the risk of 
developing AF. However, their sensitivity analysis among GERD patients treated with 
PPIs and those not treated with PPIs showed a significant association between PPIs and 
AF. There were not enough prescription claims for H2RAs from the database to support 
an effective analysis. Only 53 of the 40,484 members showed a paid prescription claim 
for an H2RA prior to their index date. When the relationship between PPIs and AF were 
assessed among only PPI and H2RA users, an OR of 1.68 [0.88 – 3.19] was calculated. 
This suggested a possible association, however in future studies, more than just 0.13% of 
the sample size would need to show H2RA exposure in order for a similar analysis to be 
worthwhile. 
Related epidemiologic studies to come may find more definitive results by matching on 
the basis of age so that all included participants have the same chance of developing AF 
as well as needing PPI therapy for other age-related conditions. Another aspect for future 
consideration would be the length of PPI therapy. More conclusions may be drawn when 
investigating new vs. long-term users of PPI.  
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A large omission of this study was clinical information, namely, laboratory results. 
Though it was not possible on the large scale of this study, future assessments of 
electrolyte and electrocardiography laboratory values would demonstrate a more 
complete account of the AF/PPI relationship. As hypomagnesaemia has been an observed 
effect of PPI therapy and a known cause of AF, a more in-depth assessment of 
magnesium levels among participants would be especially valuable. Another significant 
omission here that may be improved in future studies is the record of non-prescription 
drug exposure.  
Future settings where clinical values and a more comprehensive medication record may 
be available for future studies include Veterans Affairs Medical Centers and long-term 
care institutions. Both offer comprehensive medical care to patients and excel in 
documenting laboratory results and full medication regimens. Both have patient 
populations with comparable ages and risk factors. Medication records are typically 
reliable and complete due to either on-site administration or favorable co-pays.  
Conclusion 
This nested case-control study found that exposure to PPI therapy was more likely in 
insurance members who were diagnosed with incident AF than in members without an 
AF diagnosis. This study is in agreement with case reports detailing first-time arrhythmia 
diagnoses following PPI therapy, the arrhythmia case-control study conducted by 
Marcus, et al, and with the sensitivity analysis from Huang, et al among patients with a 
GERD diagnosis. While this study adds to the body of evidence suggesting that PPIs may 
lead to AF, the meager number of members with a redeemed prescription for a 
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comparison drug limit its ability to declare with more certainty that the observed 
association between PPIs and AF are likely independent of GERD. 
The strengths of this study include a large sample size, the use of incidence density 
sampling, and a sensitivity analysis with an appropriate comparator drug. The limitations 
of this study include not matching cases and controls based on age, a lack of clinical 
values such as BMI or laboratory tests, and the inability to account for the extent of non-
prescription usage. 
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TABLE 1                         PATIENT CHARACTERISTICS 
Characteristics Entire Study Sample 
 Frequency % of Total 
Age   
0-49 16,017 39.56 
50-59 7,890 19.49 
60-69 6,502 16.06 
70-79 5,288 13.06 
≥80 4,787 11.82 
Gender   
Male 22,122 54.64 
Female 18,361 45.35 
Race   
White 31,902 79.44 
Black 1,887 4.70 
Hispanic 2,274 5.66 
Other 4,095 10.20 
Overweight/Obese 415 1.03 
Congestive Heart Failure 1,653 4.08 
Myocardial Infarction 418 1.03 
Diabetes Mellitus 2929 7.23 
Hypertension 7334 18.12 
Valvular Disease 1787 4.41 
Hyperthyroidism 122 0.30 
Chronic Kidney Disease 565 1.40 
Alcoholism 118 0.29 
Receiving NSAID therapy 1082 2.67 
Receiving diuretic therapy 3,846 9.50 
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TABLE 2                                BIVARIATE ANALYSIS 
Characteristics Cases 
n=20,265 (%) 
Controls 
n=20,219 (%) 
P value 
Age   <0.001 
0-49 1,874 (9.2%) 14,143 (70%)  
50-59 4,046 (20%) 3,844 (19%)  
60-69 4,979 (24.6%) 1,523 (7.5%)  
70-79 4,828 (23.8%) 460 (2.3%)  
≥80 4,538 (22.4%) 249 (1.2%)  
Gender   <0.001 
Male 12,371 (61%) 9,751 (48.2%)  
Female 7,894 (39%) 10,467 (51.8%)  
Race   <0.001 
White 16,967 (83.7%) 14,935 (73.9%)  
Black 842 (4.2%) 1,045 (5.2%)  
Hispanic 571 (2.8%) 1,703 (8.4%)  
Other 1,742 (8.5%) 2,353 (11.6%)  
Overweight/Obese 341 (1.7%) 74 (0.4%) <0.001 
Congestive Heart Failure 1,634 (8.1%) 19 (0.09%) <0.001 
Myocardial Infarction 409 (2%) 9 (0.04%) <0.001 
Diabetes Mellitus 2,623 (12.9%) 306 (1.5%) <0.001 
Hypertension 6,691 (33%) 643 (3.2%) <0.001 
Valvular Disease 1,753 (8.7%) 34 (0.17%) <0.001 
Hyperthyroidism 108 (0.5%) 14 (0.07%) <0.001 
Chronic Kidney Disease 535 (2.6%) 30 (0.2%) <0.001 
Alcoholism 94 (0.5%) 24 (0.1%) <0.001 
Receiving NSAID therapy 707 (3.5%) 375 (1.9%) <0.001 
Receiving diuretic therapy 3205 (15.8%) 641 (3.2%) <0.001 
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TABLE 3                         MULTIVARIABLE ANALYSIS 
 Unadjusted OR [95% CI] p-value Adjusted* OR [95% CI] p-value 
PPI 3.53 [3.12 – 3.99] p<0.001 1.98 [1.63 – 2.41] p<0.001 
*Adjusted for gender, age group, and diuretic use 
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